Hib vaccine side effects: PedvaxHIB vs ActHIB vs Hiberix, VAERS data, trials and schedule
Side-effect reports for the Hib vaccine from sourced pharmacovigilance data — VAERS and pharmacovigilance donut charts by category. Counts are database reports, not proven vaccine-caused injury rates.
How to read database counts: Pharmacovigilance systems (VAERS, EudraVigilance, Yellow Card, VigiBase, Lareb, DAEN) collect spontaneous, unverified reports. A report is not a confirmed adverse event and does not prove the vaccine caused the outcome. Under-reporting, stimulated reporting, and missing denominators limit rate interpretation. Compare with trials and epidemiological studies on each page before drawing conclusions.
Gold Standard EO (Aug 10, 2026)Federal recommendation status: Recommended for all children
The August 10, 2026 Executive Order on Gold Standard Childhood Vaccine Recommendations places Haemophilus influenzae type B (Hib) in the Recommended for all children category. The EO also expresses a preference, to the maximum extent feasible, for administering all childhood immunizations at separate medical visits.
This page summarizes published pre-licensure clinical trial data, post-licensure surveillance findings, and peer-reviewed epidemiological studies for Hib conjugate vaccines currently licensed in the United States. Safety and efficacy data are presented without interpretive language that implies the vaccine is "safe" or "unsafe." Data are drawn from FDA review documents, clinical trials, VSD analyses, VAERS summaries, IOM/National Academies reports, and peer-reviewed literature.
Evidence state
For each outcome: the specific question, what controlled studies found, and how certain that evidence is on the GRADE scale (high, moderate, low, very low). Ratings are editorial judgments by the site applying GRADE to the studies in the table below — observational evidence starts at low and is rated up for large, consistent effects or a dose/age gradient, and down for inconsistency or imprecision (Methods). Where an effect is confined to a subgroup (for example young males), the question says so. "Not searched" means no controlled study has been compiled here yet; it is not a finding that the outcome is rare or caused by the vaccine.
Outcome & question
Finding & certainty
Why this rating
Type 1 diabetes
Hib conjugate vaccine
no increased risk detected Low certainty
Finnish trial-cohort comparison and a US case-control study, consistent nulls. Studies: Karvonen 1999, DeStefano 2001.See table
Anaphylaxis
Not searched
No controlled-study result is compiled for this outcome yet.
Myocarditis or pericarditis
Not searched
No controlled-study result is compiled for this outcome yet.
Guillain-Barré syndrome
Not searched
No controlled-study result is compiled for this outcome yet.
Febrile seizure
Not searched
No controlled-study result is compiled for this outcome yet.
Immune thrombocytopenia
Not searched
No controlled-study result is compiled for this outcome yet.
1. Basic Information
Disease Protected Against
Haemophilus influenzae type b (Hib) is a bacterial pathogen that primarily affects children <5 years. Before vaccination, Hib was the leading cause of bacterial meningitis in U.S. children, as well as epiglottitis, septic arthritis, pneumonia, and bacteremia. Hib meningitis has a case-fatality rate of ~3–6% and causes permanent neurological sequelae (hearing loss, developmental delay) in 15–30% of survivors. Nontypeable H. influenzae (NTHi) strains, which are not covered by the Hib vaccine, cause otitis media and respiratory infections in children and adults but not invasive disease at the same rates.
All products require a booster dose at 12–15 months
Source: CDC ACIP, 2025 Child & Adolescent Immunization Schedule. Note: PedvaxHIB (Merck, PRP-OMP conjugate) requires only a 2-dose primary series at 2 and 4 months plus a booster at 12–15 months.
Structured composition for 3 branded products covered on this page,
taken from FDA-approved package inserts (DailyMed / manufacturer prescribing information).
Lists are per product — formulations differ by manufacturer and presentation.
Click an ingredient name to open its safety-context page when available.
Ingredient lists are sourced from official package inserts for the specific brands named above.
Formulations can change between lots and over time — verify against the current label before any clinical decision.
Presence of a substance does not by itself indicate harm; toxicology is dose-, route-, and context-dependent.
Browse the full ingredient database:
Vaccine Ingredients index.
Causality assessment & potential mechanisms
Conditions below combine WHO-style causality levels with potential biological mechanisms
from the site mechanism catalog
(ae_mechanisms_catalog.json).
HRSA VICP table listing (where shown) indicates a compensable temporal association under U.S. program rules —
not automatic proof of causation for every case. Mechanisms are hypothesis-level pathways with graded evidence.
Pre-existing or newly formed IgE against vaccine antigens or excipients (e.g., gelatin, egg proteins, PEG, polysorbate) triggers mast-cell and basophil degranulation with systemic mediator release.
SIRVA
0–2 days
Very likely / Probable
Evidence: High
SIRVA — incorrect injection into shoulder structures (primary · procedural)
Needle placement into the subdeltoid/subacromial bursa or joint rather than deltoid muscle causes prolonged local inflammation and restricted range of motion (procedural, not antigen-specific).
Framework: WHO causality + HRSA VICP (where applicable) + AE mechanism catalog.
Last updated: 2026-07-18.
Schema: schemas/vaccine_injury_table.schema.json
· Mechanisms: schemas/ae_mechanism.schema.json.
Not medical or legal advice.
2. Pre-Licensure Clinical Trial Data
Licensure trial design (ICAN / OpenVAERS)
The table below reproduces ICAN’s No Placebo Table rows for U.S. childhood-schedule products relevant to this page — including the control/comparator used in FDA licensing trials (not always saline placebo). OSMF presents this for transparency; it is not an endorsement of ICAN interpretations.
Vaccine
Brand
Manufacturer
Doses (schedule)
Ages injected
Control / comparator
Placebo
Safety review window
Hib
ActHIB
Sanofi
3 or 4
2M 4M 6M 12M
HepB
No
30 days
Hib
Hiberix
GSK
3 or 4
2M 4M 6M 12M
HibTITER or other vaccine
No
31 days
Hib
Liquid PedvaxHIB
Merck
3 or 4
2M 4M 6M 12M
Lyophilized PedvaxHIB
No
3 days
Source: OpenVAERS — No Placebo Table · ICAN original PDF
· Attribution: Informed Consent Action Network (ICAN) via OpenVAERS
· Last fetched: 2026-07-16.
For many trials listing '6 months' safety review, ICAN notes review was typically ~30 days post-injection with a phone call at 6 months.
The first Hib polysaccharide vaccine (unconjugated) was licensed in 1985 but was poorly immunogenic in infants <18 months. The first conjugate vaccine (PRP-D, ProHIBIT) was licensed in 1987. Current PRP-T and PRP-OMP conjugate vaccines were licensed between 1989–1993. Pivotal trials enrolled several thousand infants each.
Metric
Data
Evidence Strength
Combined pre-licensure safety database
~10,000+ infants across all conjugate products
Moderate
Efficacy (invasive Hib disease)
~95–100% in clinical trials
Strong
Seroprotection (anti-PRP ≥0.15 µg/mL)
~90–100% after primary series
Strong
Most Common Adverse Reactions
Reaction
Frequency (Approx.)
Injection site pain/tenderness
~10–25%
Injection site redness/swelling
~5–10%
Fever >38°C
~5–15%
Irritability
~15–30%
Drowsiness
~10–20%
Sources: Respective prescribing information; FDA review documents. Adverse reactions are generally mild and self-limited (1–3 days). Local reaction rates are higher when Hib is given as part of combination vaccines (Pentacel, VAXELIS).
Key Limitations
No true placebo: Most trials used other vaccines as comparators due to ethical constraints, limiting absolute risk attribution.
Combination products: Modern Hib vaccination is predominantly via combination vaccines (Pentacel, VAXELIS), making it difficult to isolate Hib-specific adverse events from those attributable to co-administered antigens (DTaP, IPV).
Carrier protein effects: Different Hib conjugates use different carrier proteins (tetanus toxoid, OMP). The long-term safety implications of repeated carrier protein exposure in combination schedules are not fully characterized.
3. Post-Licensure Safety Data
VSD and VAERS
Hib vaccines have an extensive post-licensure safety record with >30 years of U.S. data. VSD and VAERS surveillance have not identified unexpected safety signals. Key findings:
No association between Hib vaccination and serious adverse events, SIDS, or neurodevelopmental outcomes has been identified in VSD studies.
VAERS data are consistent with clinical trial reactogenicity profiles. No confirmed safety signals beyond those identified in pre-licensure trials.
IOM (2012) reviewed Hib vaccine and found evidence inadequate to accept or reject causality for most rare outcomes, reflecting the low frequency of adverse event reports and limited targeted post-licensure studies (relative to more controversial vaccines).
⚠ Critical Caveat
VAERS data represent unverified reports temporally associated with vaccination. A report to VAERS does not mean the vaccine caused the event.
VAERS reports per million doses
U.S. VAERS reports for vaccinations given 2006–2024, divided by the 281 million doses distributed in the same years (HRSA, from CDC data).
All reports
126
per million doses (125–127) · 35,410 reports
Serious reports
19.7
per million doses · 5,558 reports (death, life-threatening, hospitalised or disabled)
Reports with a death
3.25
per million doses · 915 reports
These are reporting rates: they mix real reactions, coincidental events and reports of conditions that would have happened anyway, and they depend on how actively each vaccine is watched. Doses are distributed, not administered. Combination vaccines count toward each component in both numerator and denominator. Compare with the observed-vs-expected analysis and the controlled studies above. Data: vaers_reporting_rates.json.
All vaccines, per million doses
Vaccine
All
Serious
Death
pcv
266
28.1
3.23
rotavirus
157
27.9
4.08
hpv
335
25.3
2.00
hib
126
19.7
3.25
polio
152
17.6
2.77
mmr
320
15.3
0.94
varicella
372
14.1
0.84
hepatitis-b
110
12.7
2.15
meningococcal
214
11.8
0.70
dtap
132
11.2
1.31
hepatitis-a
152
8.5
0.58
influenza
68
5.4
0.48
What controlled safety studies found
Unlike VAERS counts, these studies compare vaccinated people with a control group or control time window, so they can estimate whether a risk is raised and by how much. 3 results for Hib vaccines: 1 found an increased risk of a specific outcome, 2 found no increased risk.
Outcome
Design & population
Estimate (95% CI)
Excess per million doses
Finding
Source
Medically attended fever, 1-2 year olds
Pentacel (DTaP-IPV-Hib)
group sequential cohort vs historical DTaP recipients (VSD) Children 1-2 y, US
Days from vaccination to onset in U.S. VAERS reports (0–180 days). A causal reaction usually starts inside a characteristic window; but people also report what happens soon after a shot, so each event is compared with all other reports for this vaccine. The Weibull shape measures bunching (below 1 = most onsets early).
Event
Reports
Median days
In risk window
Shape (95% CI) vs others
Reading
Seizure (any)
6,275*
1
96% (others 97%)
0.74 (0.73–0.76) vs 0.66
spread later than other reports
Febrile seizure
1,681
1
97% (others 97%)
0.80 (0.76–0.84) vs 0.66
spread later than other reports
Intussusception
970
9
62% (others 40%)
0.87 (0.84–0.90) vs 0.66
spread later than other reports
Sudden infant death
835
3
75% (others 91%)
0.81 (0.77–0.86) vs 0.66
spread later than other reports
Syncope
261
0
80% (others 77%)
0.67 (0.61–0.82) vs 0.66
same timing as other reports
ADEM / encephalitis
126
3.5
75% (others 41%)
0.78 (0.70–0.92) vs 0.66
spread later than other reports
Anaphylaxis
110
0
94% (others 77%)
0.65 (0.54–1.13) vs 0.66
same timing as other reports
Immune thrombocytopenia
85
14
96% (others 41%)
1.23 (0.95–1.88) vs 0.66
spread later than other reports
Kawasaki disease
78
7.5
79% (others 41%)
0.74 (0.65–0.86) vs 0.66
same timing as other reports
Herpes zoster
73
81
33% (others 41%)
0.67 (0.55–0.88) vs 0.66
same timing as other reports
Stroke
46
3
80% (others 40%)
0.69 (0.58–0.97) vs 0.66
same timing as other reports
Guillain-Barré syndrome
41
9
88% (others 41%)
0.99 (0.81–1.29) vs 0.66
spread later than other reports
Timing alone cannot establish causation; it can make it more or less plausible. *Fitted on a random sample of 5,000 of these reports. Data: vaers_onset.json.
VAERS Reporting Data — Halma & Varon (2025), DARE-SAFE
The DARE-SAFE paper (Halma & Varon, Pharmacoepidemiology 2025, CC BY 4.0) analyzed VAERS reports for vaccines administered in the United States from 2006–2022. The following data are extracted from Table 1 of that paper for this vaccine (HiB (all Hib products combined)):
Metric
Value
U.S. doses administered (2006–2022)
159,451,493
Total VAERS AE reports
21,526
AE reporting rate (per 100,000 doses)
13.5
Total death reports
435
Death reporting rate (per 100,000 doses)
0.273
AE-to-Death ratio
50:1
Source: Halma, M.; Varon, J. DARE-SAFE. Pharmacoepidemiology. 2025. DOI: 10.3390/pharma4020007. CC BY 4.0. Data from Table 1.
📚 Important Interpretive Caveats (from the paper itself)
Reporting rate ≠ incidence rate. VAERS is a passive, unverified system. A report means someone submitted a claim of temporal association, not a confirmed causal event. The paper is explicit that causality cannot be inferred from these numbers alone.
Reporting behavior is not uniform. More serious, unusual, or media-salient events are reported at much higher rates than mild ones. Products receiving more public, media, legal, and clinical attention (particularly COVID-19 vaccines, which also benefited from V-safe active-surveillance prompts and CICP compensation pathways) generate more reports per dose regardless of true risk.
Age and comorbidity confounding is not adjusted. COVID-19 vaccines were disproportionately administered to elderly and comorbid populations (nursing homes, 65+, high-risk groups in early 2021) with much higher background all-cause mortality than the general child/working-age population. Some fraction of temporally-associated deaths would occur regardless of vaccination, and the paper does not perform a background-rate comparison.
Stimulated reporting is a known, documented phenomenon. Media coverage, plaintiff attorney solicitation, and advocacy campaigns — all independently inflate VAERS reporting propensity. The paper cites this literature but does not correct for it.
Small-denominator rows are unreliable. Rates computed from small denominators (e.g., monovalent measles, DT, mumps, rubella) have enormous statistical uncertainty and should not be compared to vaccines with hundreds of millions of administered doses without noting the wide confidence intervals.
Source: Halma, M.; Varon, J. DARE-SAFE: Denominator-Adjusted Rate Estimates of Substance Adverse Events Frequency Evaluation in Pharmaceuticals and Vaccines. Pharmacoepidemiology. 2025, 4, 7. DOI: 10.3390/pharma4020007. CC BY 4.0.
Passive Surveillance: AE Type Breakdown (Multi-System)
Side-by-side view of U.S. VAERS, Health Canada Canada Vigilance, Japan JADER (PMDA), EU EudraVigilance, and live-scraped international systems via SurVigilance (VigiAccess, Lareb, DAEN, DMA, Medsafe). SurVigilance panels show MedDRA PT mention totals (not individual-case counts). Category assignment uses keyword matching — approximate, not official SOC coding. VAERS files on this site are built from the public VAERS download. FAERS figures use the public quarterly FAERS files. Counts are mentions or reports, not incidence.
VAERS (United States)
Canada Vigilance (Canada)
JADER (PMDA, Japan)
EudraVigilance (EU)
11,980 individual cases · adrreports.eu DAP export (up to 28/06/2026)
Reaction SOC breakdown not included in this workbook export.
Denmark DMA interactive ADR search is currently offline (Danish Medicines Agency IT transition; public overviews frozen at 12 Mar 2024). Live product PT tables cannot be retrieved until DKMA restores the search. See DKMA notice. Denmark continues to report into EU EudraVigilance (panel above).
Medsafe (New Zealand)
VAERS (U.S., 2006–2024): 12,006 symptom mentions (7.53/100k doses). Largest share: Other / Unclassified (79%), Injection-site / Local reaction (5%), General / Systemic (non-local) (3%). Canada Vigilance (CV Online extract): 34 reaction mentions in 17 unique reports (82.3% serious (14 of 17 reports)). Largest share: Dermatological (non-injection-site) (21%), Autoimmune / Immune-mediated (12%), Allergic / Anaphylactic (9%). JADER (PMDA public CSV extract): 193 reaction mentions in 144 unique reports (8.3% serious (12 of 144 reports)). Largest share: Neurological (27%), Other / Unclassified (20%), General / Systemic (non-local) (17%). EudraVigilance (EU DAP export): 11,980 individual cases (up to 28/06/2026). Reaction SOC categories were not exported in the local DAP workbooks — case count only. VigiAccess (WHO): 234,603 reaction-term mentions · search: Hib. Largest share: Other / Unclassified (22%), General / Systemic (non-local) (18%), Injection-site / Local reaction (13%). Lareb (Netherlands): 254 reaction-term mentions · search: Haemophilus influenzae type b vaccine. Largest share: Other / Unclassified (18%), General / Systemic (non-local) (17%), Cardiac / Cardiovascular (15%). DAEN (Australia): 1,824 reaction-term mentions · search: Haemophilus influenzae. Largest share: Other / Unclassified (25%), Psychiatric / Neuropsychiatric (16%), General / Systemic (non-local) (16%). Medsafe (New Zealand): 46 reaction-term mentions · search: Hib. Largest share: Gastrointestinal (30%), General / Systemic (non-local) (22%), Neurological (15%). Cross-database note: All systems are passive and unverified; reporting rates are not directly comparable across countries (different populations, reporting incentives, and lack of dose denominators for Canada/Japan/EU). top VAERS: Other / Unclassified; top Canada Vigilance: Dermatological (non-injection-site); top JADER: Neurological. SurVigilance note: VigiAccess, Lareb, DAEN, DMA, and Medsafe counts are live-scraped MedDRA PT mention totals (not deduplicated individual cases). Data via SurVigilance (GPL-3.0; pip install SurVigilance). Category assignment uses keyword matching on reported reaction terms — approximate and exploratory. Neither database establishes causality.
Pharmacovigilance Lot Signal Detection — Hypothesis-Generating Only
Multi-system context below. VAERS (U.S.) supports lot-level volume z-scores and seriousness flags by product and lot (2006–2026). Each lot links to a summary with report count, seriousness %, adverse-event pie chart, U.S. state map, and timeline. A signal flag means a statistical threshold was exceeded — not that a lot is unsafe. Full dashboard →
VAERS flags:VOL high report volume (z ≥ 3) ·
BURST clustered in <90 days ·
SER serious reports >50%.
Lot numbers are voluntary/incomplete in VAERS. Location data is U.S. state only (no postal codes in the public extract).
VAERS (United States) — all lots by product
3,064 reports with usable lot across 427 lots · 33 flagged
Loading lot tables…
Other Pharmacovigilance Systems
Lot-level analysis is only possible where reporters supply batch/lot numbers in the public extract. Canada Vigilance, JADER (PMDA, Japan), and most other national systems publish product-level spontaneous reports without lot fields.
Canada Vigilance spontaneous reports are unverified temporal associations. The public CV Online data extract does not include lot or batch numbers, so lot-level signal detection is not possible for this system — only product-level reaction patterns are shown here. No Canadian dose denominators are available. Extract 2026-03-31.
144 unique reports · 193 reaction mentions · 8.3% serious (12 of 144 reports). Top categories: Neurological (27%), Other / Unclassified (20%), General / Systemic (non-local) (17%).
JADER (Japanese Adverse Drug Event Report database) spontaneous reports are unverified temporal associations; PMDA has not assessed causality per case. The public CSV extract does not include lot or batch numbers, so lot-level signal detection is not possible — only product-level reaction patterns are shown here. Reaction terms in source data use MedDRA/J Preferred Terms. JADER CSV extract pmdacasereport202606 (2026-06). JADER reference (PDF)
11,980 individual cases (up to 28/06/2026) · HAEMOPHILUS TYPE B CONJUGATE VACCINE. Reaction SOC breakdown not included in this DAP export.
EudraVigilance spontaneous reports are unverified temporal associations. The local EudraVigilance DAP workbooks provide individual-case counts from adrreports.eu; exported Reaction SOC filters were not set, so reaction-category charts are unavailable from this extract. Lot/batch numbers are not in public line listings.
Active Pharmacovigilance (Defined-Population Surveillance)
Curated findings for Hib conjugate vaccines from active systems (not VAERS). Page inventory last reviewed: 2026-07-10.
ⓘ Active vs. passive — why this pane is separate
The VAERS / multi-system charts above are passive surveillance: spontaneous, unverified reports without a fixed denominator.
Active surveillance starts from a defined, enumerated population (EHR/claims or structured post-vaccination surveys), applies pre-specified statistical tests, and asks whether an outcome occurs
more often than expected in a risk window versus a comparison window or group.
These are not two flavors of the same evidence — active findings are the harder tier that can confirm, refute, or leave under investigation a signal first hinted in passive data.
Do not add VAERS report counts to active incidence rates.
○ No signal detected◐ Signal under investigation◑ Investigated — not confirmed● Signal confirmed (true association)– Not currently under active surveillance
CDC Vaccine Safety Datalink (VSD)
Outcome: Serious outcomes in infant schedule co-administration context
Tier 2○ No signal detected
Hib conjugates transformed invasive Hib epidemiology. Active surveillance historically supported a favorable serious-risk profile; routine monitoring continues within combination-schedule studies rather than as a high-intensity standalone RCA focus.
Population
Infants at VSD sites
Risk interval
Study-specific
Comparison
Control intervals
Evaluation period
Post-conjugate introduction (late 1980s onward)
Method
Historical and ongoing observational monitoring of conjugate Hib products
Update cadence: Tier 1: check AusVaxSafety monthly when public pages update. Tier 2/3: quarterly review around ACIP meetings and PubMed/MMWR; set lastReviewed per record.
Source tiers: Tier 1 = public near-real-time dashboards (e.g. AusVaxSafety);
Tier 2 = VSD / Sentinel / PRAC-type findings released via ACIP slides, MMWR, or papers (no public VSD raw dashboard);
Tier 3 = regulator label/safety communications.
Detecting a signal and later classifying it as not confirmed is normal system behavior — not an anomaly to hide or amplify.
4. Documented Adverse Events
Rank-aggregated VAERS signal detection (rankv)
No pairs mapping to this product family appear in the rank-aggregated common-signal set from rankv (intersection of GPS, PRR, ROR, and BCPNN signals). That does not mean absence of all VAERS reports — only that no pair met the four-method consensus filter in the published pipeline.
Data: ~30 years of public VAERS (rankv processed tables).
Origin: precisionFDA “Gaining New Insights by Detecting Adverse Event Anomalies” challenge solution.
Caveat: Disproportionality signals are statistical associations in spontaneous reports. They do not establish causality, incidence, or product defect. Many top pairs reflect administration/product-use coding rather than clinical injury.
▶ Published Evidence Does Not Support a Causal Association
SIDS: No association. No Association
Type 1 diabetes: Studied; no association found. No Association
5. Disease Prevention Benefits
Metric
Pre-Vaccine Era
Post-Vaccine Era
Invasive Hib disease (annual, children <5)
~20,000 cases (~40–100 per 100,000)
<50 cases (<1 per 100,000) — >99% reduction
Hib meningitis (annual)
~12,000 cases; leading cause of acquired intellectual disability
<30 cases/year
Hib deaths (annual, children <5)
~600–800
<5/year
Source: CDC Pink Book; MMWR. The Hib vaccine has near-eliminated invasive Hib disease in the U.S. Vaccination also reduces nasopharyngeal carriage, providing herd protection to unvaccinated children.
Disease Burden Over Time
Reported U.S. disease burden by year. The dashed vertical line marks vaccine introduction. Hover or tap data points for values; use arrow keys when a chart has focus.
ⓘ About these charts: These are accessible SVG line charts with keyboard navigation, hover tooltips, and an underlying data table (expand below). The dashed vertical line marks the year of vaccine introduction. Reported cases undercount true incidence; case definitions, reporting practices, and diagnostic methods have changed over time. See Section 5 for additional context and pre-vs-post era comparisons.
7. Evidence Summary
Hib conjugate vaccines have been in U.S. use for >35 years with a well-established safety and effectiveness profile. Pre-licensure trials were moderate in size but post-licensure data from national surveillance and VSD are extensive. The Hib vaccine is among the most effective in the pediatric schedule, with >99% reduction in invasive disease. No significant post-licensure safety signals have been identified.
Domain
Evidence Grade
Invasive Hib disease prevention
Strong
Common adverse events
Strong
Rare adverse events
Moderate
8. International Surveillance & Global Data
Quick links to public pharmacovigilance databases and trial registries relevant to Hib Vaccine. Reporting counts do not establish causality.
Note: Spontaneous reports are unverified observations. Compare with epidemiological studies in Sections 3–6 before drawing conclusions.
9. Curated Adverse Event Literature
Curated peer-reviewed literature linking specific adverse events to Hib Vaccine. Each entry is a case report, case series, or related safety publication identified via PubMed. Expand Search PubMed for additional literature below to run custom queries.
Disclaimer: Published reports describe observations and associations; they do not establish population incidence or causality.
Common questions
How long do Hib vaccine side effects last?
Most reported Hib vaccine reactions are short-lived: injection-site soreness, tiredness, and low-grade fever that typically begin within a day or two and resolve within a few days. Longer-lasting or more serious events are rarer and are the ones tracked in the post-licensure surveillance and documented adverse-event sections of this page, with report counts that are not incidence rates. Anything severe or persisting beyond a week warrants medical review.
Is the Hib vaccine given to adults, and are side effects different in adults?
Whether the Hib vaccine is recommended for adults depends on the vaccine and the person's risk factors; the schedule and product sections above describe the licensed indications and age groups. Reporting patterns in adults can differ from children, so this page's VAERS and international database breakdowns should be read with the reporting population in mind. Check the current CDC/ACIP adult schedule and the product's prescribing information for adult dosing.
10. Key References
IOM. Adverse Effects of Vaccines: Evidence and Causality. National Academies Press; 2012. nationalacademies.org